# MOLECULAR CANCER RESEARCH

## TABLE OF CONTENTS

### HIGHLIGHTS

1249  Selected Articles from This Issue

### REVIEW

1251  Emerging Roles for AKT Isoform Preference in Cancer Progression Pathways  
Seamus E. Degan and Irwin H. Gelman

### CANCER GENES AND NETWORKS

1258  EGR1 Addiction in Diffuse Large B-cell Lymphoma  

1270  Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Coregulator in Invasive Lobular Carcinoma of the Breast  

1283  Mutant KRAS Downregulates the Receptor for Leukemia Inhibitory Factor (LIF) to Enhance a Signature of Glycolysis in Pancreatic Cancer and Lung Cancer  
Suhu Liu, Helen I. Gandler, Isidora Tosić, Darwin Q. Ye, Zachary T. Giaconne, and David A. Frank

1296  Protein Kinase D-Dependent Downregulation of Immediate Early Genes through Class IIA Histone Deacetylases in Acute Lymphoblastic Leukemia  
Guangyan Sun, Anna Shvab, Guy J. Leclerc, Bin Li, Felipe Beckedorff, Ramin Shiekhattar, and Julio C. Barredo

### CANCER "-OMICS"

1308  Genomic Landscape of Primary and Recurrent Anal Squamous Cell Carcinomas in Relation to HPV Integration, Copy-Number Variation, and DNA Damage Response Genes  
Jordan Aldersley, David R. Lorenz, Kent W. Mow, Alan D. D’Andrea, and Dana Gabuzda

1322  Quantitative Proteomics Identifies Secreted Diagnostic Biomarkers as well as Tumor-Dependent Prognostic Targets for Clear Cell Renal Cell Carcinoma  
Aydanur Senturk, Ayse T. Sahin, Ayse Armutlu, Murat C. Kiremit, Omer Acar, Selcuk Erdem, Sidar Bagbudar, Tarik Esen, Nurcan Tuncbag, and Nurhan Ozlu

### GENOME MAINTENANCE

1338  Autophagy-Dependent Sensitization of Triple-Negative Breast Cancer Models to Topoisomerase II Poisons by Inhibition of the Nucleosome Remodeling Factor  

1350  CHK2 Inhibition Provides a Strategy to Suppress Hematologic Toxicity from PARP Inhibitors  
Zhen Xu, Cassandra J. Vandenbark, Elizabeth Lischke, Radha Di Rago, Clare L. Scott, and Jan I. Majewski

1361  R-Loop-Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin  
Invasive lobular carcinoma of the breast (ILC) is the most common special subtype of breast cancer, and though nearly all ILC express estrogen receptor alpha (ERα), ILC represent a distinct context for ERα function among breast cancers. The cover depicts a stylized immunofluorescence image showing DNA damage foci to which Mediator of DNA Damage Checkpoint 1 (MDC1) has localized. MDC1 canonically acts in the DNA damage response. However, in their study on page 1270, Sottnik, Bordeaux, and colleagues provide evidence that MDC1 also has novel ERα co-regulator activity and is critical for ERα function in ILC cells. The authors argue that canonical functions of MDC1 in DNA repair may be superseded by novel ERα co-regulator activity in this context. Artwork by Kristine M. Sikora, PhD.
Molecular Cancer Research

19 (8)


Updated version
Access the most recent version of this article at:
http://mcr.aacrjournals.org/content/19/8

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://mcr.aacrjournals.org/content/19/8.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.